Patent court to review Alexion's Soliris patents on Amgen challenge: filings

Patent court to review Alexion's Soliris patents on Amgen challenge: filings
Reuters: Health
The U.S. patent office will review three patents on Alexion Pharmaceuticals Inc's drug Soliris, after rival Amgen Inc filed a petition challenging them, court filings showed on Friday.


Comments

Post a Comment

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

The PIL argued that persons with mental illnesses were chained in a faith-based mental asylum in Budaun district of Uttar Pradesh in violation of provisions of the Mental Health Care Act 2017. The court examined the photos of such patients calling it a matter of great concern. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/hG1drmq via gqrds
Read more

Women in India Report Higher Sleep Deprivation Than Men

The survey, conducted by Resmed, gathered insights from 30,000 people across 13 countries, including 5,000 respondents in India. The findings highlight a growing recognition of sleep as a health priority and underlined a persistent gaps in achieving consistent, quality rest. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/14OaF7t via gqrds
Read more

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018

According to the National Health Authority's (NHA) annual report 2024-25, over 40.45 crore Ayushman cards were issued till March 31, covering 14.69 crore families and eighty-two per cent of beneficiaries are from rural areas, with 94 per cent having Aadhaar-verified cards, ensuring authenticity and inclusivity, the report stated. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/JRnLlcK via gqrds
Read more